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Abstract: In order to contribute to a better knowledge of the events involved in the formation of the 
protein corona when nanoparticles (NPs) come in contact with proteins, we report a study about the 
changes on the physicochemical properties of pristine, PEGylated and Cyclic Arginine-Glycine-
Aspartate peptide (RGD)-functionalized large unilamelar liposomes (LUVs) or magnetoliposomes 
(MLs) upon incubation with Bovine Serum Albumin (BSA). The main phospholipid component of both 
LUVs and MLs was L-α-phosphatydylcholine (PC) or 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(DMPC) with 20% of cholesterol. The most obvious indication of the interaction of BSA-nanosystems is 
given by changes in the hydrodynamic diameter of the particles but other evidence is needed to 
corroborate the process. Our findings indicate that size modification is a process that is accomplished in 
few hours and that is strongly dependent not only on the surface decoration but also of the lipid 
composition of both LUVs and MLs. Fluorescence quenching experiments as well as cryogenic 
transmission electron microscopy (Cryo-TEM) images assessed these changes and confirmed that 
although each system has to be studied in a particular way, we can establish three distinctive features 
that turn into more reactive systems: (a) compositions containing PC compared with their DMPC 
counterparts; (b) the presence of PEG and/or RGD compared to the pristine counterparts; and (c) the 
presence of SPIONs: MLs show higher interaction than LUVs of the same lipid composition. 
Consequently, PEGylation (that is supposed to make stealth NPs) actually fails in preventing complete 
protein binding. 
Keywords: magnetoliposomes; liposomes; BSA; protein corona; fluorescence anisotropy; 
fluorescence quenching 
 
1. Introduction 
Liposomes are among the first colloidal soft particles described and could be considered one of 
the pioneers of the current nanoparticle family. Since their discovery by the end of the 1950s, their 
application has kept growing for their vast potential in several fields, mainly biomedical [1–6]. One 
of the most interesting features of these biocompatible and biodegradable lipid vesicles is related to 
their tunable composition that can be designed for a specific purpose and has resulted in a continuous 
evolution of liposome structure in recent years. Initially, the basic changes to modulate bilayer 
properties were related to modifications in phospholipid composition—namely polar head charge, 
saturation, length of the acyl chains, and the introduction of additives such as cholesterol [7–9]. 
However, these changes could not solve one of the main drawbacks that appeared upon liposome 
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administration in vivo which is their rapid recognition and uptake by cells of the mononuclear 
phagocyte system leading to their quick removal and thus, reduced half life time in the blood stream. 
This problem was partially overcome by the decoration of the outer leaflet of the bilayer with anti-
opsonization agents mostly polymers, especially polyethylene glycol (PEG) generating thus the 
commonly known as stealth liposomes [10–12]. PEG creates a steric barrier between the liposomal 
surface and the biological medium resulting in a shielding of these nanostructures from 
immunological recognition and loss of stability. By the PEG approach, surface-surface interactions 
including the aggregation of liposomes and/or adsorption of plasma proteins are reduced [13] but 
not totally prevented [14]. More recently, with the main aim of effectively delivering drugs and 
improving their therapeutic index and reducing their undesired side effects, liposomes have been 
tailored by attaching particular components to the outer part of the bilayer like peptides [15–17] to 
reach specific targets such as cancer or malaria-infected cells [18–20]. Among the peptides, the 
Arginine-Glycine-Aspartate (RGD) triad has been often selected as nanoparticles scaffold for 
displaying a strong affinity and selectivity to the αV β3 integrin that is overexpressed in malignant 
tissues. Therefore, RGD attachment to Large Unilamellar Vesicles (LUVs) or Magnetoliposomes (MLs) 
surface may provide efficient vehicles for therapeutics or contrast agents for the treatment or 
diagnosis, respectively, of diseases such as thrombosis, osteoporosis, and cancer [21,22]. 
From all the information mentioned above, it could be concluded that based on the properties 
of the target, liposomes could be easily and successfully designed for a specific drug delivery purpose 
or as diagnostic systems. However, studies in vitro and in vivo have shown that, in many occasions, 
liposomes do not reach the expected location upon their contact with the biological environment as 
a consequence of the rapid adsorption of proteins, thus immediate formation of a protein shell or 
corona around the particles is prevented [23–25]. Consequently, liposomes with very specific 
targeting moieties on their surface do not always result in an improved accumulation at the target 
tissues [26]. It is also known that the characteristics and properties of the corona are strongly 
dependent on protein source to determine the fate of particle uptake as has been described lately 
[27,28]. 
Several surface modifications have been developed in order to modulate or minimize the protein 
corona. The first one has already been mentioned and consists on the introduction of PEG groups in 
the lipid bilayer, but the success is not complete because of the residual protein adsorption and the 
uncertainties in the mechanism of PEG-lipid stabilization. It has also been described that zwitterionic 
nanoparticles lack a protein corona [29]. Nevertheless, corona formation cannot be completely 
prevented even with the presence of PEG that reduces protein adsorption without lack of cellular 
uptake [30]. 
The determination of the corona and the comprehension of its dependence on the nanoparticle 
properties has become of capital importance in nanoscience as can be stated by the large amount of 
published papers in the last few years. In this aspect, Lundqvist et al. [31] have reported that even for a 
specific material type, the size of the particle, and its surface modification can completely alter the protein 
corona and probably their biological impact. Corona proteins can physically mask the nanoparticle 
surface, potentially affecting the therapeutic effect of the molecules bound to the nanoparticle surface [32]. 
On another hand, it has also been described that cellular uptake is strongly related to the nature of the 
proteins that constitute protein corona [33]. For instance, it has been found that albumin pre-loading 
increased the macrophage uptake of PPEylated(polyphosphoester) nanocarriers while it was decreased 
when these same nanocarriers where loaded with clusterin. Schöttler et al. [34] have found that, in 
presence of proteins, PEGylated nanocarriers incubated with 10% of fetal bovine serum were not taken 
up by HeLa cells in contrast with the high uptake observed in absence of a previous incubation. Not only 
altered plasma protein composition due to different diseases affects the protein corona but also, the 
composition of the corona varies among healthy individuals [35]. Thus, the protein source is a crucial 
factor in the formation of the corona. 
The protein corona-nanoparticle conjunction has raised the interest of many groups regarding 
not only liposomes but other organic (nanorods, carbon nanotubes) or inorganic particles 
(superparamagnetic iron oxide nanoparticles, gold nanobones) [36–39]. However, even if the protein 
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corona can be understood as a problem in nanoparticle uses for biomedical applications, one can take 
profit of this apparent drawback and turn what is a problem into a new strategy for developing 
formulations for a specific purpose [35,40–42]. Recently, new molecular targets have been described 
from identification of the type of proteins that form the corona [43]. In the same trend, fluids enriched 
with hard corona proteins favored the faster release of the payload compared to those bearing soft 
coronas [36]. This new approach, attractive in view to the development of personalized medicine, 
requires a good knowledge of the nature of the proteins that form the corona and of the mechanism 
of protein-nanoparticle interaction [44,45]. 
Considering the aforementioned, and due to the insufficient knowledge about the interaction of 
liposomes with the biological environment—which make difficult any prediction of the biological 
outcomes—we present a study of the behavior of LUVs and hybrid LUVs containing superparamagnetic 
iron oxide nanoparticles (SPIONs), named magnetoliposomes (MLs), in presence of bovine serum 
albumin (BSA). BSA binds to nanoparticles and changes their physicochemical properties. The BSA-
nanoparticles complex has enhanced penetration capability in the biological membrane over bare 
nanoparticles. To analyze the influence of surface composition on the interaction, these systems were 
decorated with polyethylene glycol (PEG) or the cyclic peptide RGD. Therefore, we report the results 
obtained with three types of LUVs or MLs: pristine, PEGylated, and RGD functionalized. L-α-
phosphatydylcholine (PC) and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) were the main 
phospholipids chosen for the synthesis of the lipid vesicles for their differences in the acyl chain. The BSA-
LUVs or BSA-MLs interactions were characterized by several methods such as fluorescence, isothermal 
microcalorimetry (ITC), dynamic light scattering (DSC), transmission electron microscopy (TEM and 
Cryo-TEM), and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). These 
independent techniques provided similar qualitative results indicating that BSA interactions with LUVs 
and MLs are strongly dependent on lipid composition. Our findings are in agreement with the reports of 
several authors that conclude about the difficulty of drawing a general trend and that all the systems need 
to be studied in a particular way. However, from our studies, we can draw three facts that seem to guide 
the interactions and increase the magnitude of the binding: (a) compositions containing PC compared 
with their DMPC counterparts; (b) the presence of PEG and/or RGD compared to the pristine 
counterparts and; (c) the presence of SPIONs: MLs show higher interaction than LUVs of the same 
lipid composition. 
2. Results and Discussion 
2.1. Physicochemical Characterization of Liposomes and Magnetoliposomes 
The lipid composition, hydrodynamic diameter (hd), polydispersity index (PDI), and ζ of pristine, 
PEGylated, and RGD conjugated LUVs or MLs are summarized in Table 1. These measurements were 
made prior to BSA incubations to set them as control values. All formulations presented low PDI 
values (<0.200) indicating a mono-modal and narrow size distribution. TEM and Cryo-TEM images 
showed (see Figure 1) well-dispersed round-shaped vesicles with a size that correlates that of 
dynamic light scattering (DLS) measurements. 
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Figure 1. Cryo-TEM images of: (a) PC-RGD-LUVs; (b) PC-RGD-MLs; (c) PC -RGD-MLs incubated 24 h 
with BSA; (d) DMPC-RGD-LUVs; (e) DMPC-RGD-MLs; and (f) DMPC -RGD-MLs incubated 24 h with 
BSA. Scale in all the images is 100 nm except for (c) which is 500 nm. 
Table 1. Physicochemical characterization of LUVs and MLs of different composition before 
incubation with BSA: hd: hydrodynamic diameter; PDI: polydispersity index and ζ: zeta potential. PC: 
L-α-phosphatydylcholine; DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine; PEG: 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt); PEG*: 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000] 
(ammonium salt) (DSPE-Mal-PEG-2000); CHOL: cholesterol, and RGD: Cyclic RGD-(D-Phe)-C. Molar 
ratios into brackets. 
Lipid Composition 
hd/nm PDI ζ/mV 
LUVs MLs LUVs MLs LUVs MLs 
PC/CHOL (8:2) 170.4 ± 1.0 178.5 ± 6.4 0.090 ± 0.041 0.136 ± 0.048 −1.85 ± 0.85 −7.5 ± 0.43 
PC/CHOL/PEG (8:2:0.3) 161.8 ± 3.7 114.0 ± 7.6 0.119 ± 0.032 0.129 ± 0.05 −16.6 ± 0.20 −18.9 ± 4.23 
PC/CHOL/PEG*/RGD  
(8:2:0.3:0.03) 
136.2 ± 1.5 175.1 ± 1.4 0.146 ± 0.011 0.200 ± 0.01 −13.0 ± 0.90 −27.0 ± 0.35 
DMPC/CHOL (8:2) 180.0 ± 3.6 191.5 ± 6.9 0.122 ± 0.018 0.200 ± 0.02 −4.66 ± 0.92 −1.23 ± 0.96 
DMPC/CHOL/PEG (8:2:0.3) 154.9 ± 4.5 168.7 ± 6.6 0.163 ± 0.024 0.139 ± 0.06 −14.8 ± 0.14 −15.7 ± 0.40 
DMPC/CHOL/PEG*/RGD  
(8:2:0.3:0.03) 
183.1 ± 4.2 198.0 ± 5.2 0.149 ± 0.023 0.135 ± 0.02 −26.3 ± 0.95 −22.5 ± 0.83 
2.2. Physicochemical Characterization of BSA Corona-Coated Liposomes and Magnetoliposomes 
Serum albumins are the major soluble protein constituents of the circulatory system and are 
essential for several physiological functions as the transport of a number of compounds. Therefore, 
the understanding of its interaction with lipid vesicles could contribute to the design of liposomes 
with a particular composition to improve the delivery of drugs to a specific target. Bovine serum 
albumin (BSA) has been chosen for the present study due to its structural homology with human 
serum albumin (HSA). 
Protein corona was allowed to form onto vesicles by incubating the LUV or ML formulations 
with BSA at 37 °C for 2, 4, or 24 h. No significant changes were observed at these incubation times 
thus confirming the data found in the literature where several authors indicate the formation of the 
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protein corona very quickly after the incubation of other types of nanoparticles with plasma proteins 
[25]. 
Isolation of liposomes from loosely-bound and unbound BSA was performed by size exclusion 
chromatography. Strong centrifugation was excluded to prevent alterations in vesicle-protein 
interactions. 
2.2.1. Changes in Size, Polydispersity Index, and Zeta Potential Corroborate the Interaction of BSA 
with LUVs and MLs 
The formation of the protein corona is usually manifested as an increase in the mean 
nanoparticle diameter since a layer of protein molecules is deposited onto their surface. In the case of 
liposomes, the interaction with proteins is more complex as a consequence of their elastic and softer 
structure which can result in two opposite effects, a reduction due to an osmotically driven shrinkage 
or an increase in their hd [42]. According to this statement, our results indicate a different behavior 
depending on not only lipid composition but also on the presence or not of SPIONs into the liposomes 
(Table 2). 
Table 2. Changes in size, polydispersity index (PDI) and ζ potential of LUVs or MLs upon incubation 
with 1 mg·mL−1 (ca. 16 μM) BSA for 24 h. The values are expressed as increases calculated by 
subtracting the initial value to the value after incubation. Pristine-PC or DMPC: PC/CHOL (8:2) or 
DMPC/CHOL (8:2); PEGylated PC or DMPC: PC/HOL/PEG (8:2:0.3) or DMPC/CHOL/PEG (8:2:0.3) 
and RGD-PC or DMPC: PC/CHOL/PEG*/RGD (8:2:0.3:0.03) or DMPCPC/CHOL/PEG*/RGD 
(8:2:0.3:0.03). 
Lipid 
Composition 
LUVs MLs 
Δ Size/nm Δ PDI Δ ζ/mV Δ Size/nm Δ PDI Δ ζ/mV 
Pristine-PC Aggregated >1  Aggregated >1  
PEGylated-PC Aggregated >1  Aggregated >1  
RGD-PC Aggregated >1  Aggregated >1  
Pristine-DMPC ~0 0.017 −25.25 ± 16.53 4.50 ± 2.6 0.070 −4.24 ± 4.35 
PEGylated-DMPC ~0 0.014 −0.73 ± 1.00 24.0 ± 5.2 0.085 −16.93 ± 3.59 
RGD-DMPC ~0 0.014 −25.25 ± 2.05 Aggregated >1  
The results indicated in the table correspond to increases in the hd, PDI, and ζ potential after 
incubation with BSA for a period of 24 h at 37 °C, with respect to the initial values before incubation. 
Of the two phospholipid compositions studied, it is clear that the samples containing PC are unstable 
in the presence of BSA. Aggregation and formation of a thick precipitate was visible just after 
LUVs/MLs-BSA mixing and it was impossible to separate free BSA from BSA-LUVs or MLs 
complexes by size exclusion chromatography. Contrarily, DMPC LUVs are stable regardless of the 
surface decoration. The presence of SPIONs in the same lipid composition creates a different behavior. 
Pristine and PEGylated MLs become slightly larger without PDI significant changes indicating that 
the samples remain homogeneous, while RGD-DMPC MLs are clearly unstable in the presence of 
BSA behaving as PC samples. According to the predictions of the dense spherical model [46] the 
smallest aggregate containing two identical spheres of diameter hd results in a particle with size 
corresponding to 2hd. Therefore, these little changes in size are not compatible with the formation of 
a thick corona [47] and could reflect the particle coating with a thin layer of BSA. 
ζ potential was not possible to determine in the case of aggregated samples and, in general, 
becomes more negative than the original samples in agreement with literature reports assessing the 
presence of BSA in the outer leaflet of the liposome [43]. 
TEM and Cryo-TEM have been used to visualize the changes associated to the protein corona 
formation. As an example of the most evident interaction, we show in Figure 1 images of LUVs (left) 
and MLs (middle) of PC-RGD (top panel) and DMPC-RGD (bottom panel). The pictures on the right 
panels correspond to MLs incubated 24 h, at 37 °C, with BSA. It can be seen how, after incubation, 
morphology of the MLs is dramatically altered, especially for the PC composition (500 nm scale in 
contrast to the other images in which it is of 100 nm). 
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2.2.2. SDS-PAGE Evidences the Presence of BSA in LUVs and MLs 
BSA associated with the samples after incubation for 24 h was separated by SDS-PAGE and 
visualized with Coomassie Blue staining (Figure 2). The panel on the left corresponds to the 
incubation of LUVs while the one on the right refers to the incubation with MLs. SDS-PAGE of MLs 
show a greater intensity of the BSA band compared to its non-magnetic counterpart, suggesting that 
the presence of SPIONs on the vesicles also affects the interaction between the nanoparticle and BSA. 
PC-MLs bands (1–4, right panel) showed higher intensity than DMPC-MLs (5–8, right panel). Among 
the last ones, it is difficult to understand why the DMPC-MLs band (5) shows less intensity than the 
DMPC-Chol band (6). It could be attributed to previously-mentioned observation that, in general, 
DMPC samples are less reactive and the differences observed among DMPC-MLs are not significant. 
To discard the influence of pure phospholipids in the interaction, bare PL-LUVs or PL-MLVs (PL: PC 
or DMPC) were also applied to the gel. 
 
Figure 2. SDS-PAGE of: (left) LUVs and (right) MLVs after 24 h incubation with BSA at 37 °C. The 
order of the bands is from left to right: 1: Bare PC; 2: bare PC/Chol; 3: PEGylated-PC; 4: RGD-PC; 5: 
bare DMPC; 6: bare DMPC/Chol; 7: PEGylated-DMPC; and 8: RGD-DMPC. 
2.2.3. Fluorescence Analysis of BSA Binding to LUVs or MLs 
Fluorescence Quenching 
BSA has two intrinsic tryptophan (Trp) residues, one at the surface exposed to the medium and 
another buried inside the protein [48] that act as a fluorophores. The changes in fluorescence intensity 
of both Trp residues may be due to a direct quenching or as a consequence of a change on the protein 
conformation upon BSA-Lipid interaction. The fluorescence quenching refers to any process that 
decreases the intensity of a fluorophore caused by a variety of molecular interactions with a quencher 
molecule and depends upon the accessibility of the quencher molecules to the fluorophores. 
Fluorescence quenching is a useful approach to get insight into the understanding of the 
interaction of compounds of several sources with body proteins [49]. Thus, fluorescence quenching 
has been used to measure the binding affinities between the liposomes and BSA. Figure 3, illustrates 
the influence of the presence of LUVs of different composition on the fluorescence spectra of BSA and 
Table 3 shows a summary of the results after treatment of the data according to Equations (1) and (2). 
The fluorescence intensity decreased gradually with the increase in the concentration of LUVs or MLs, 
implying an interaction between the protein and the lipid vesicles. 
Table 3. KSV calculated from the fluorescence spectra of BSA upon increased additions of LUVs or 
MLs of different composition. 
Lipid Composition 
LUVs MLs 
Ksv/L·mol−1 r Ksv/L·mol−1 r 
Pristine-PC 345 ± 6 0.994 2465 ± 30 0.996 
PEGylated-PC 4460 ± 22 0.997 1908 ± 27 0.997 
RGD-PC 963 ± 15 0.995 2151 ± 13 0.996 
Pristine-DMPC 500 ± 12 0.992 1237 ± 20 0.999 
PEGylated-DMPC 840 ± 10 0.996 1685 ± 35 0.997 
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RGD-DMPC 1300 ± 21 0.994 1739 ± 24 0.999 
We assume that the changes in the BSA spectrum come from their interaction with the lipids 
and that the quenching constant can be taken as the binding constant of the complex formation [50]. 
The calculations were based on the changes of the maximum fluorescence emission wavelength (λmax) 
of BSA that was found to be 338 nm. For all the samples, the lipid addition results in a decrease in the 
fluorescence intensity maximum in a similar magnitude except for the PEGylated samples and, 
especially, for PEGylated-PC (Figure 3). The decrease occurs just after the first addition that 
corresponds to a PEGylated-PL/BSA molar ratio of ~12.5/1. This modification of fluorescence 
intensity might be due to the quenching of the Trp residues present in the BSA molecule. The 
fluorescence quenching is usually classified in two types, dynamic or collisional and static. Dynamic 
quenching results from the diffusion of the quencher and the fluorophore in the medium and does 
not modify the absorption spectra because it only affects the excited state of the fluorophore. Upon 
the contact, the fluorophore returns to the ground state without emission of a photon. Therefore, a 
dynamic quencher agent provides a non-radiative route for loss of the excited state energy. On 
another hand, static quenching is a consequence of the formation of a dark complex (non-fluorescent) 
in the ground state between the quencher molecules and the fluorophore that is assessed by a change 
in the absorption spectra. 
Both, dynamic and static quenching require molecular contact between the fluorophore and the 
quencher and can be distinguished in the plot Fo/F vs. quencher concentration. Dynamic quenching 
is characterized by a straight line while static appears as a positive deviation. In our case, all the 
samples bended towards the x-axis, indicative of a negative deviation and consequently, static 
quenching was discarded. This kind of deviation is common in systems having accessible and 
inaccessible fluorophores, as it could be the presence of more than one Trp. That is the case of BSA 
with two Trp residues: Trp-134 located on the surface of the molecule, and Trp-212 buried in a 
hydrophobic binding pocket. However, the deviation is probably a consequence of LUV or ML 
aggregation due to the turbidity observed in the samples at high lipid concentrations. 
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Figure 3. Fluorescence spectra obtained after the incubation of BSA with PC or DMPC LUVs or MLs. 
(a) LUVs PC/Chol (8:2); (b) MLs PC/Chol (8:2); (c) LUVs DMPC/Chol (8:2); (d) MLs DMPC/Chol (8:2); 
(e) LUVs PC/Chol/PEG (8:2:0.3); (f) MLVs PC/Chol/PEG (8:2:0.3); (g) LUVs DMPC/Chol/PEG (8:2:0.3); 
(h) MLVs DMPC/Chol/PEG (8:2:0.3). The black line corresponds to the spectrum of 5 µM free BSA 
while the rest refer to the recordings after consecutive additions of 5 µL of 20 mM LUVs or MLs. The 
arrow indicates the direction of increase in LUVs or MLs concentration ranging from 62 to 370 µM 
into the reaction cuvette. λexc: 280 nm. The intensity of the emission band at 338 nm corresponding to 
the tryptophan was used for the calculation of the Stern-Volmer constant (KSV) [51]. 
Particularly interesting are the results obtained when the titration is made with PEGylated-PC 
because the decrease in fluorescence intensity is accompanied by a blue shift. This change reaches 12 
nm when the molar ratio PEGylated-PC/BSA is ~300/1. In that case, apart from the quenching 
phenomena, spectral shifting is associated to Trp exposure to changes in the polarity as a consequence 
of the interactions with its environment. Thus, polarity of the chromophores of the BSA (two Trp 
residues present in each BSA molecule) decreased and the hydrophobicity increased. The quenching 
mechanism can be unravelled from the Stern-Volmer equation (Equation (1)) that allows the 
calculation of KSV. Although strong ligand-protein complexes are characterized by lipid-BSA 
association constants (KSV) with values ranging from 105 to 108 M−1, some authors have reported 
interactions with lower KSV values consistent with our results [51]. According to the Hill model [52], 
KSV can be considered to be reciprocal to the dissociation constant KD (≈1/KSV) for certain conditions 
though KD refers to equilibrium and 1/KSV to non-equilibrium conditions. We have not considered 
this approach because of the evidence of only collisional quenching and the lack of trustable results 
when calculating KD from KSV [53]. In addition, Fleischer and Payne [54] pointed out that data 
obtained with physicochemical experiments were significantly different from those found with other 
methods, consequently suggesting caution in assuming that KD can be deduced from KSV. In 
agreement with previous results, ML samples showed more significant changes in BSA spectra and 
consequently, KSV is higher. Remarkable and unexpected was the high value of the Stern-Volmer 
constant for PEGylated-PC reflecting a higher BSA binding compared to the other lipid compositions. 
Consequently, PEGylation (that is supposed to make NPs stealth) actually fails in preventing 
complete protein binding. On another hand, fluorescence spectra of BSA remained unchanged upon 
titration of the cuvette with SPIONs. This indicates that BSA binding to the nanoparticles is only 
related to the properties of the outer leaflet of the bilayer determined by the lipid composition and 
the attached peptide. 
Fluorescence Anisotropy 
The purpose of the anisotropy measurements was to analyze the structural changes on the lipid 
membrane during BSA binding to LUVs or MLs. Thus, the dynamics of lipids in LUV or ML 
membranes in the presence of BSA was determined by measuring the degree of depolarization of the 
fluorescence (Equation (2)) emitted from the hydrophobic probe TMA-DPH, which is anchored at the 
water/lipid interface due to its charged trimethylammonium group. r values are high at temperatures 
below the main transition of the lipid, from gel to liquid crystalline state due to the highly-restricted 
rotation for the probe. Experiments were only performed with the samples containing DMPC because 
of its well-defined Tm at 23 °C in contrast with PC that has a Tm below 0. r remained unchanged after 
BSA addition to the cuvette that contained DMPC-LUVs or DMPC-MLs, regardless of the surface 
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composition. Considering that the working temperature was above Tm, the lack of changes in r could 
be attributed to an increase in surface rigidity due to the presence of BSA around the LVs or MLs. 
2.2.4. Thermotropic Behavior of LUVs and MLs in Presence of BSA 
The calorimetric experiments were only performed with the samples containing DMPC as the 
main phospholipid for having well-defined thermotropic properties in contrast to those of PC. 
Differential Scanning Calorimetry (DSC) 
In lipid bilayers, lipid phase behavior is sensitive to the presence of exogenous compounds on 
surfaces and this effect was considered as a tool to study the interaction of LUVs and MLs with BSA. 
As far as the controls without BSA are concerned, DMPC exhibited the characteristic main transition 
at ~24.4 °C, the addition of a 20% cholesterol resulted in the appearance of a shoulder at a higher 
temperature indicative of a broadening of the melting region while the main transition disappeared 
upon the addition of a 3% PEG. Consequently, RGD presence gave the same profile as the 
DMPC/CHOL/DSPC-PEG mixture. For that reason, changes due to BSA presence in the media was 
only evaluated with DMPC or DMPC/Chol samples. Significant differences were observed between 
LUVs and MLs. BSA did not change either the shape or the energy of DMPC main transition in LUVs. 
However, this transition completely disappeared in MLs and could be attributed to the presence of 
the encapsulated SPIONs. 
Isothermal Titration Calorimetry (ITC) 
The binding properties of the LUVs and MLs with BSA were consecutively studied using ITC. 
The total heat produced endothermally was plotted while injecting BSA in LUVs or MLs at 37 °C 
(Figure not shown). The molar ratios PL/BSA ranged from 0.28/1 in the first addition to 7.1/1 after the 
last (30th), similar to those studied in the fluorescence section. Results did not show any significant 
binding and no thermodynamic parameters could be obtained as shown for the lack of differences 
between the heats for the LUVs or MLs and the dilution heats of BSA. Thus, the binding of the LUVs 
or MLs seem to be weak as observed with fluorescence experiments. 
3. Methods 
3.1. Materials 
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (DSPE-mPEG-2000), 
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000] 
(ammonium salt) (DSPE-Mal-PEG-2000) were obtained from Avanti Polar Lipids (Alabaster, AL, 
USA) and cholesterol (CHOL) from Sigma (Barcelona, Spain). L-α-phosphatydylcholine (PC) was 
procured from Lipoid (Ludwigshafen, Germany). Cyclic RGD-(D-Phe)-C (with an amide bond) 
peptide was synthesized by CASLO Laboratory ApS (Kongens Lyngby, Denmark). Iron (II) chloride 
tetrahydrate (FeCl2·4H2O) and iron (III) chloride hexahydrate (FeCl3·6H2O) were purchased from 
Sigma Aldrich (St. Louis, MO, USA). Polyethylene glycol (PEG) of 6000 Da average molecular weight 
was obtained from VWR International (Barcelona, Spain). Ammonium hydroxide (NH4OH, 25%) was 
provided by Panreac (Barcelona, Spain). Deionized Millipore Milli-Q water was used in all 
experiments. Bovine Serum Albumin (BSA) was purchased from Sigma Aldrich (St. Louis, MO, USA). 
The fluorescent probe 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p-
toluenesulfonate (TMA-DPH), was from Molecular Probes, Inc (Eugene, OR, USA). A strong 
neodymium-iron-boron (Nd2Fe12B) magnet (1.2 T) was obtained from Halde GAC (Barcelona, Spain). 
All other chemicals were from Sigma (St. Louis, MO, USA), were of analytical grade, and were used 
without purification. 
3.2. Methods 
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3.2.1. Preparation and Characterization of Liposomes and Magnetoliposomes 
PL and mixtures of PL/CHOL (8:2 molar ratio), PL/CHOL/DSPE-PEG (8:2:0.3 molar ratio) or 
PL/CHOL/DSPE-PEG-Maleimide/RGD (8:2:0.3:0.03 molar ratio), being PL: PC or DMPC, were 
prepared by dissolving appropriate amounts of lipid in chloroform/methanol (2:1 v/v). After solvent 
evaporation under reduced pressure, the resulting lipid films were hydrated with ultrapure water 
and after soft sonication in a bath sonicator, LUVs were prepared by the extrusion of the preparations 
10 times through 200 nm pore-size poly-carbonate filters (Nucleopore) in a low pressure extruder 
(Lipex, Biomembranes, Vancouver, BC, Canada). The phospholipid content was determined by the 
Steward–Marshall method [55]. The calibration curve was performed with the same different lipid 
mixtures in chloroform that the used in the study. Absorbance was measured in a Shimadzu UV-2401 
PC UV-vis spectrophotometer (Shimadzu, Tokyo, Japan). For the preparation of MLs, a similar 
procedure was followed but the lipid film was hydrated with a ferrofluid (FF) solution, a suspension 
of SPIONs instead of water. Non encapsulated FF was separated from the loaded into liposomes by 
gel exclusion chromatography with Sepharose 4B (Pharmacia Fine Chemicals, Uppsala, Sweden). FF 
was prepared according to the method described by García-Jimeno et al. [56]. Iron content was 
determined spectrophotometrically following the method of Kiwada [57]. 
LUVs or MLs size before and after incubation with BSA was measured at different times from 
their preparation depending on the assay. 2% (w/v, ~0.31 mM) BSA and 25 mM LUVs or MLs were 
mixed at a ratio of 1:1 (v/v), resulting in a final PL/BSA molar ratio of ~83/1. The hydrodynamic 
diameter (hd) and the corresponding polydispersity index (PDI) were determined by dynamic light 
scattering at a fixed scattering angle of 90° with a Zetasizer Nano (Malvern, UK) at 25 °C and 37 °C. 
LUVs or MLs from the stock solution were dispersed in water to obtain approximately 0.1 g·L−1 solid 
content. 
Geometry of LPs and MLs was observed by transmission electron microscopy (TEM) and cryo-
TEM. For TEM observations, a Jeol 1010 microscope (Jeol, Tokyo, Japan) operating at 80,000 kV was 
used. Samples were prepared by placing a drop of MLs onto a 400-mesh copper grid coated with 
carbon, and after staining with uranyl acetate they were allowed to dry in the air before being placed 
into the microscope. Images were recorded with a Megaview camera. Acquisition was accomplished 
with the Soft-Imaging software (SIS, Schwentinental, Germany). For cryo-TEM observations, grids 
were transferred to a Tecnai F20 (FEI, Eindhoven, The Netherlands) using a cryoholder (Gatan, 
Warrendale, PA, USA). Images were taken at 200 kV, at a temperature ranging from −175 to −170 °C 
and using low-dose imaging conditions with a 4096 × 4096 pixel CCD Eagle camera (FEI, Eindhoven, 
The Netherlands). 
The zeta potential of the dispersion was measured diluted in 10−3 M potassium chloride solution 
with a Zeta Sizer Nano Series (Malvern Instruments, Worcestershire, UK) at 20 °C. 
3.2.2. Isothermal Titration Calorimetry (ITC) 
ITC measurements were performed using a MicroCal VP-ITC (Northampton, MA, USA) with 
an effective cell volume of 1.4199 mL and feedback mode: high. The experimental temperature was 
kept constant at 37 °C. The number and injected volume of the titration steps were the same for all 
measurements (30 × 10 μL). The initial delay was set to 60 s. 
The working cell was filled with a liposome suspension (containing 0.01 mM lipid) in water and 
the reference cell with liposome-free water. Ten-microliter aliquots of 0.0625 mM BSA were injected 
stepwise into the working cell at 340 s intervals. 
The generated ITC data were collected automatically by the Windows-based Origin Software 
also supplied by MicroCal (one set of sites binding model) which uses a nonlinear least-squares 
algorithm (minimization of X2). To fit the heat flow per injection into an equilibrium binding equation, 
the software uses titrant and sample concentrations. It provides best fit values of the stoichiometry 
(n), involved enthalpy (ΔHb(ITC)), and binding constant (Kb(ITC)) at working conditions. Additionally, 
the same amount of BSA was titrated into pure water to determine the heat of dilution for reference. 
The integrated reference heats were then subtracted from the integrated heats of the adsorption 
experiments. All titrations were measured in triplicates. The corresponding reference blank 
Nanomaterials 2017, 7, 37 11 of 16 
 
experiments were also performed, namely titration of the liposome suspension with water and 
titration of water with BSA solution. 
3.2.3. Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry was carried out by means of a Metller-Toledo DSC-822e 
calorimeter. Experimental conditions were as follows: aluminum crucibles of 40 μL volume; 
atmosphere of dry nitrogen with 50 mL/min flow rate; heating rates of 1–40 °C/min. The 
concentration of lipids was 20 mM. Data acquisitions measured at least three scans for lipid DMPC 
were collected between 5 °C and 45 °C at 10 °C/h. Buffer subtraction and baseline correction were 
performed using Microcal Origin software (Microcal Inc. Worcestershire, UK). The calorimeter was 
calibrated with indium of 99.99% purity. Lipid and BSA were mixed at a molar ratio of 83/1. 
3.2.4. SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
30 μL of the BSA incubated liposomes were added to 10 μL of 4× loading buffer [180 mM Tris-
HCl pH 6.8, 40% glycerol, 0.05% bromophenol blue, 10% sodium dodecyl sulfate (SDS) and 20% β-
mercaptoethanol] and the mixture was heated at 95 °C for 10 min. After centrifugation of the samples 
~3 min at 8000 rpm (Eppendord centrifuge) they were resolved on 12% SDS-PAGE gels, stained with 
Coomassie Brilliant Blue and scanned at high resolution. 
3.2.5. Fluorescence Spectroscopy 
Fluorescence experiments were performed in an Aminco Bowman AB2 (Microbeam, SA, 
Barcelona. Spain) spectrofluorimeter adapting the procedure described by Charbonneau and Tajmir-
Riahi [58]. A 5 μM BSA solution (in double distilled water) was titrated with different volumes of 
liposomes (initial concentration 20 mM). The fluorescence spectra were recorded in a range of 300 to 
450 nm at an excitation wavelength (λex) of 280 nm (slit-widths: 4 nm). Then, the quenching of BSA 
in the presence of LUVs was calculated from the changes on the tryptophan (Trp) fluorescence of the 
protein at 338 nm (BSA maximum fluorescence emission intensity) with the Stern-Volmer equation 
(Equation (1)) 
𝐹o
𝐹
= 1 + 𝐾sv [𝑄] (1) 
where Fo and F are the steady state fluorescence intensities in absence and presence of liposomes 
(quencher in our case), respectively, Ksv is the Stern-Volmer quenching constant. 
Corrections for dilution were done by repeating the experiments after adding the same volumes 
of water to the cuvette containing BSA. 
3.2.6. Fluorescence Anisotropy 
Steady-state anisotropy measurements were carried out with the same spectrofluorimeter 
mentioned above using L-format fluorescence polarizers. The dynamics of LUVs in presence of BSA 
was determined by measuring the degree of depolarization of fluorescence emitted from the probe 
TMA-DPH. The excitation (λex) and emission (λem) wavelengths were 365 nm and 425 nm, 
respectively (slit-widths: 4 nm). DMPC LUVs or MLs were incubated at 40 °C (above Tm of the lipid) 
for at least 1 h before use to allow the probe to be incorporated. The initial concentration of lipid in 
the cuvette was 150 μM, which corresponds to a ratio lipid/probe of 700/1. BSA was added from a 5 
µM stock solution in sequential additions of 5 µ L. Anisotropy values were corrected from dilution. 
Anisotropy (r) measurements were done at 25 °C and 37 °C with the same equipment described 
before and was calculated automatically by the software provided with the instrument, according to 
Equation (2): 
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𝑟 =
𝐼𝑉𝑣 − 𝐺𝐼𝑉ℎ
𝐼𝑉𝑣 + 2𝐺𝐼𝑉ℎ
  (2) 
where IVv and IVh are intensities of the emitted polarized light with the emission polarizer parallel (Vv) 
or perpendicular (Vh), respectively, to the excitation polarizer and, G is the instrument sensitivity 
ratio towards vertically and horizontally polarized light [59]. 
Control experiments were performed with BSA alone to check the lack of interference between 
the emissions of the fluorophores of the protein (Trp) and the probe (TMA-DPH). 
4. Conclusions 
The present study compares the behavior of LUVs and MLs differing on surface properties in 
presence of BSA by several techniques that take into consideration different experimental conditions 
such as lipid/BSA molar ratios or physical chemistry properties. The rationale of surface modification 
with cyclic RGD with enhanced stability over the lineal form was aimed to functionalize MLs and 
LUVs for nanoparticle tumor targeting to integrins rich in RGD receptors that are over expressed in 
cancer cells. On another hand, the encapsulation of SPIONs was intended for their use as diagnostic 
systems. We have shown that the characteristics of liposomes can change upon exposure to BSA, 
which is strongly dependent on the lipid composition. The presence of the unsaturated PC as the 
main component of the bilayer makes the systems more reactive in contrast to the saturated DMPC. 
Moreover, further functionalization of the liposomes via PEGylation and/or attachment of RGD 
shows an enhancement of the reactivity between liposomes and BSA. This effect may be caused by a 
different type of interaction occurring. In BSA-Pristine systems, interaction is mainly hydrophobic 
while for BSA-PEGylated systems interactions is basically electrostatic. Similarly, the incorporation 
of SPIONs into the nanosystems results in more reactive systems. One general problem for 
unravelling the doubts remaining in protein-nanosystem interaction is that, although numerous 
studies exist, many of them are hard to compare, as there is a lack of quantitative parameters which 
could be used as metrics for direct comparison. In our case, size and Ksv were the only parameters 
rendering useful data to distinguish nanosystem-BSA interaction. Qualitative binding was observed 
with SDS-PAGE that also confirmed the presence of larger amounts of BSA in PC LUVs or MLVs 
than in DMPC systems. In any case, neither the presence of PEG nor RGD reduce the interaction 
probably as a consequence of the electrostatic interactions present in these nanoparticles. Therefore, 
even though the results reported indicate the need to study all the nanosystems in a particular 
manner, there are three general trends that spread among all tests performed. The presence of 
SPIONs enhances reactivity between BSA and liposomes, as well as the compositions containing PC 
compared with their DMPC counterparts, and also the presence of PEG and/or RGD compared to the 
pristine counterparts. However, these effects need to be studied further in order to obtain more 
quantitative data and better understand these behaviors. Also the influence of SPIONs in the results 
is an item to be further investigated. 
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DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
CHOL Cholesterol 
FF Ferrofluid 
hd Hydrodynamic diameter 
LUVs Large unilamellar vesicles 
MLs Magnetoliposomes 
NPs Nanoparticles  
PC L-α-phosphatydylcholine 
PDI Polydispersity Index 
PEG 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] (ammonium salt) 
PEG* 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide 
(polyethylene glycol)-2000] (ammonium salt) (DSPE-Mal-PEG-2000) 
PL Phospholipid 
RGDc Cyclic arginine-glycine-aspartate peptide 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
Cryo-TEM Cryogenic transmission electron microscopy 
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